The T-cell response to SARS-CoV- 2 vaccination persists beyond six months in rheumatoid arthritis patients treated with rituximab
Even if RTX treatment prevented the SARS-CoV- 2 vaccine-dependent antibody response in RA patients, a strong spike protein-specific T-cell-mediated response that persisted for up to 18 months after the last SARS-CoV- 2 boost was found in RA RTX patients. With respect to personalized medicine, analyzing the spike protein-specific T-cell response might be a valuable strategy for deciding when revaccination is necessary.
Authors
- Nathalie Balandraud (ORCID: https://orcid.org/0000-0002-3839-0185)
- Pierre Lafforgue (ORCID: https://orcid.org/0000-0001-8478-8023)
- Juliette Marin (ORCID: https://orcid.org/0000-0001-7356-1026)
- Claudia Cartagena
- P Bourgoin (ORCID: https://orcid.org/0000-0002-9970-2680)
- Jean‐Marc Busnel (ORCID: https://orcid.org/0000-0001-6651-2437)
- Noemie Saverna
Institutions
- Assistance Publique Hôpitaux de Marseille (FR)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1186/s13075-025-03553-4
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00